

REMARKS

Claim 1 has been cancelled. Claims 74 - 121 have been added. Accordingly, claims 74-121 are currently pending in the application. Support for new claims 74 to 82, 84, 112, and 113 can be found throughout the specification, including at least at page 3, lines 25-35, page 7, lines 14-17, page 12, lines 17-18, page 13, lines 11-22, and page 27, lines 20-21. Support for new claim 83 can be found throughout the specification, including at least at page 29, line 28 to page 32, line 35. Support for new claims 85, 100, 115, and 119 can be found at least at page 4, lines 1-12 and page 29, lines 14-16 and 23-27 of the specification. Support for new claims 86, 101, 116, and 120 can be found throughout the specification, for example, at page 4, lines 28-31. Support for new claims 87, 102, 117, and 121 can be found throughout the specification, including at least at page 12, lines 15-17. Support for new claims 88 and 103 can be found at page 29, line 28 to page 32, line 35 of the specification, and support for new claims 89, 90, 104, and 105 can be found at page 29, line 28 to page 31, line 12. Support for new claims 91, 92, 106, and 107 can be found in the specification at page 31, lines 13-30, while support for new claims 93, 94, 108, and 109 can be found at page 31, lines 13 to page 32, line 6. Support for new claims 95, 96, 110, and 111 can be found in the specification, for example, at page 32, lines 7-27. Support for new claims 97, 98, 112, and 113 can be found at page 32, lines 28-35. Additional support for new claims 114-121 can be found at page 40, line 17.

For the Examiner's convenience, a copy of the claims as they will be pending upon entry of this amendment is set forth in Appendix A. Applicants amend the specification of this application to correct for an inadvertent typographical error in Table 4 and to include drawings 1 to 9. The foregoing amendment is not related to issues of patentability, and introduces no new matter. A "Version With Markings to Show Changes Made" is attached herewith.

No new matter has been added. The foregoing claim amendments and cancellations should in no way be construed as an acquiescence to any of the Examiner's rejections, and have been made solely to expedite the prosecution of the application. Applicant reserves the right to pursue the claims as originally filed in this or a separate application(s).

Rejection of Claim 74 Under 35 U.S.C § 101


The Examiner has issued a double patenting rejection for claim 74 under 35 U.S.C § 101. Applicants have cancelled claim 1, thereby rendering the double patenting rejection moot.

SUMMARY

In view of the foregoing remarks, reconsideration of the rejections and allowance of all pending claims is respectfully requested. It is respectfully submitted that any amendments and/or cancellations of the claims should in no way be construed as an acquiescence to the Examiner's rejections and/or objections.

If a telephone conversation with Applicants' Attorney would expedite the prosecution of the above-identified application, the Examiner is urged to call Applicants' Attorney at (617) 227-7400.

Respectfully submitted,



Giulio A. DeConti, Jr., Esq.
Reg. No. 31,503
for
Elizabeth A. Hanley, Esq.
Registration No. 33,505
Attorney for Applicants

LAHIVE & COCKFIELD, LLP

28 State Street
Boston, MA 02109
Tel. (617) 227-7400
Dated: March 10, 2003

VERSION WITH MARKINGS TO SHOW CHANGES MADETable 4: Apparent kinetic rate ~~rate~~ and affinity constants of D2E7 and biotinylated rhTNF

Experiment	K_a (M^{-1} , s^{-1})	K_d (s^{-1})	K_d (M)
1	1.33×10^5	9.58×10^{-5}	7.20×10^{-10}
2	1.05×10^5	9.26×10^{-5}	8.82×10^{-10}
3	3.36×10^5	7.60×10^{-5}	2.26×10^{-10}
Average	$1.91 \pm 1.26 \times 10^5$	$8.81 \pm 1.06 \times 10^{-5}$	$6.09 \pm 3.42 \times 10^{-10}$